文献速递消化内镜消化道肿瘤与早癌

前瞻性结肠镜研究:非进展期腺瘤患者一级亲属结直肠肿瘤风险调查

Prospective colonoscopic study to investigate risk of colorectal neoplasms in first-degree relatives of patients with non-advanced adenomas.
PubMed 文献 · Gut · 2019-04-26

该盲法横断面研究纳入414名非进展期腺瘤患者的一级亲属和414名年龄性别匹配的对照一级亲属,均接受结肠镜检查。暴露组进展期腺瘤患病率为3.9%,对照组为2.4%(匹配OR=1.67,95%CI 0.72-3.91,p=0.238),无显著差异;但暴露组任何腺瘤患病率更高(29.2% vs 18.6%,p<0.001)。结论认为非进展期腺瘤家族史不显著增加临床重要结直肠肿瘤风险,支持现行指南不提倡对该人群提前筛查。

要点

  • 非进展期腺瘤患者一级亲属的进展期腺瘤患病率与对照无显著差异(3.9% vs 2.4%,p=0.238)。
  • 暴露组任何腺瘤(29.2% vs 18.6%)和非进展期腺瘤(25.4% vs 16.2%)患病率均显著高于对照。
  • 两组均未检出结直肠癌,数据支持现行指南不提倡对该人群提前筛查。

核心结论

  • 非进展期腺瘤家族史不显著增加临床重要结直肠肿瘤风险,数据支持现行指南不提倡对非进展期腺瘤一级亲属提前筛查。

研究设计与样本

  • 盲法横断面研究,从结肠镜数据库连续纳入新诊断非进展期腺瘤患者的一级亲属414名(暴露组,平均年龄55.0±8.1岁)和年龄性别匹配的结肠镜正常者一级亲属414名(非暴露组,平均年龄55.2±7.8岁),每户招募一名一级亲属,排除有结直肠癌家族史者,2015年11月至2018年6月接受结肠镜检查。

主要发现

  • 进展期腺瘤患病率暴露组3.9% vs 非暴露组2.4%(匹配OR=1.67;95%CI 0.72-3.91;校正先证者性别和年龄后p=0.238)。
  • 任何腺瘤患病率暴露组29.2% vs 非暴露组18.6%(匹配OR=1.87;95%CI 1.32-2.66;p<0.001)。
  • 非进展期腺瘤患病率暴露组25.4% vs 非暴露组16.2%(匹配OR=1.91;95%CI 1.32-2.76;p=0.001)。
  • 多发性腺瘤比例暴露组4.3% vs 非暴露组2.2%(校正匹配OR=2.44;95%CI 1.01-5.86;p=0.047)。
  • 两组均未检出结直肠癌。

临床怎么用

  • 作者结论认为非进展期腺瘤家族史不显著增加临床重要结直肠肿瘤风险,数据支持现行指南不提倡对该人群提前筛查。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The risk associated with a family history of non-advanced adenoma (non-AA) is unknown. We determined the prevalence of colorectal neoplasms in subjects who have a first-degree relative (FDR) with non-AA compared with subjects who do not have an FDR with adenomas. DESIGN: In a blinded, cross-sectional study, consecutive subjects with newly diagnosed non-AA were identified from our colonoscopy database. 414 FDRs of subjects with non-AA (known as exposed FDRs; mean age 55.0±8.1 years) and 414 age and sex-matched FDRs of subjects with normal findings from colonoscopy (known as unexposed FDRs; mean age 55.2±7.8 years) underwent a colonoscopy from November 2015 to June 2018. One FDR per family was recruited. FDRs with a family history of colorectal cancer were excluded. The primary outcome was prevalence of advanced adenoma (AA). Secondary outcomes included prevalence of all adenomas and cancer. RESULTS: The prevalence of AA was 3.9% in exposed FDRs and 2.4% in unexposed FDRs (matched OR (mOR)=1.67; 95% CI 0.72 to 3.91; p=0.238 adjusted for proband sex and proband age). Exposed FDRs had a higher prevalence of any adenomas (29.2% vs 18.6%; mOR=1.87; 95% CI 1.32 to 2.66; p<0.001) and non-AA (25.4% vs 16.2%; mOR=1.91; 95% CI 1.32 to 2.76; p=0.001). A higher proportion of exposed FDRs than unexposed FDRs (4.3% vs 2.2%; adjusted mOR=2.44; 95% CI 1.01 to 5.86; p=0.047) had multiple adenomas. No cancer was detected in both groups. CONCLUSION: A positive family history of non-AA does not significantly increase the risk of clinically important colorectal neoplasia. The data support current guidelines which do not advocate earlier screening in individuals with a family history of non-AA. TRIAL REGISTRATION NUMBER: NCT0252172.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Ng SC, Kyaw MH, Suen BY, et al. Prospective colonoscopic study to investigate risk of colorectal neoplasms in first-degree relatives of patients with non-advanced adenomas. Gut. 2019. PMID: 31028155. doi:10.1136/gutjnl-2018-318117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。